GLP-1 Medications and Muscle Loss: What the 2026 Evidence Really Shows About Metabolism and Weight Regain

GLP-1 medications can produce substantial weight loss, but the scale does not tell you whether that weight came from fat, lean tissue, or both. As semaglutide, tirzepatide and other incretin-based therapies become increasingly important in obesity treatment, a more useful question is emerging: how can weight be lost while preserving muscle, physical function and long-term health?

Evidence review updated: September 28, 2026  |  Topic: GLP-1 medications, muscle loss, lean mass, metabolism and weight regain

The evidence in one paragraph: Substantial weight loss from semaglutide, tirzepatide and other incretin-based therapies can include a measurable reduction in lean mass. However, a 2026 systematic review and meta-analysis found that the proportion of total weight lost as lean mass was broadly comparable with intensive lifestyle-based weight loss, rather than showing that incretin drugs uniquely cause muscle loss. The same analysis found the most favorable lean-mass profile when resistance training was incorporated. The practical implication is not “avoid GLP-1 drugs because they destroy muscle,” but rather “treat muscle preservation as part of the weight-management plan.” [1]

On this page

• Does GLP-1 treatment cause muscle loss?
• What body-composition studies actually show
• Does losing muscle slow metabolism?
• Why does weight come back after stopping?
• Protein and muscle preservation
• Resistance training and physical function
• How to monitor muscle during weight loss
• What poison-center data really show
• What about the gut microbiome and natural GLP-1?
• A practical GLP-1 muscle-preservation framework
• What about newer obesity drugs?
• Frequently asked questions

Does GLP-1 Treatment Cause Muscle Loss?

Yes, lean mass can decrease during GLP-1 or incretin-based weight loss. But that statement needs context.

When adults lose a substantial amount of body weight through almost any method, the lost tissue is not exclusively body fat. Lean mass can decline as well. Lean mass is a broader term than skeletal muscle: it includes muscle as well as organs, body water, connective tissue and other non-fat components.

That distinction matters because headlines sometimes equate every kilogram of lost lean mass with skeletal-muscle destruction. Body-composition measurements do not justify that simplification.

A 2026 systematic review and meta-analysis of 20 randomized controlled trials involving 15,782 participants found that lean mass represented approximately 35.2% of weight lost with semaglutide, 25.4% with tirzepatide and 26.8% with liraglutide. Lifestyle interventions had a similar proportion at 26.2%, while lifestyle interventions combined with resistance training had the most favorable proportion at 17.5%. [1]

This does not mean that losing one-quarter to one-third of weight as lean mass is desirable. It means that the phenomenon is closely tied to the biology of substantial weight reduction and is not, based on current evidence, unique to GLP-1-based medications.

Important terminology: “Lean mass loss” is not synonymous with “skeletal muscle loss.” DXA and other body-composition methods estimate compartments of the body, and changes in hydration and other lean tissues can contribute to the measured result. Skeletal-muscle function therefore deserves separate attention through strength, performance and, when appropriate, more specific body-composition assessment.

What Body-Composition Studies Actually Show

One of the most useful 2025 studies came from the SURMOUNT-1 tirzepatide program. In a DXA substudy of 160 participants with obesity or overweight, tirzepatide produced a mean reduction of 21.3% in body weight, 33.9% in fat mass and 10.9% in lean mass by week 72. Approximately 75% of the weight lost was fat mass and 25% was lean mass. [2]

Finding	What the study showed	What it does not prove
Weight loss	Tirzepatide produced substantial reductions in total body weight.	That every kilogram lost was harmful or metabolically equivalent.
Fat mass	Fat mass fell substantially and accounted for most of the weight lost.	That maintaining every kilogram of lean tissue is the only meaningful outcome.
Lean mass	Lean mass also declined.	That tirzepatide selectively destroys skeletal muscle.
Proportion of loss	About three-quarters of weight lost was fat and one-quarter lean mass in the DXA substudy.	That the same ratio applies identically to every patient, dose or treatment duration.

The authors also reported that the approximate 75:25 fat-to-lean ratio remained relatively consistent across several clinically relevant subgroups. The study is useful, but it has limitations: the DXA substudy included only a small fraction of the parent trial, and the majority of authors had relationships with the drug's manufacturer. Those limitations do not invalidate the findings, but they are relevant when interpreting the evidence. [2]

Why the 2026 meta-analysis matters

The broader 2026 systematic review helps put individual drug studies into context. Across randomized trials, the researchers found that lean mass accounted for 25% to 39% of weight loss with incretin therapies, but the proportion was broadly similar to lifestyle interventions without medication.

The most favorable composition occurred when resistance training was included, with lean mass accounting for approximately 17.5% of weight lost in the pooled analysis. This finding strengthens the case for treating exercise as a core part of weight-management therapy rather than as an optional add-on. [1]

Does Losing Muscle Slow Your Metabolism?

It can contribute to lower energy expenditure, but “muscle loss slows metabolism” is an oversimplification.

Muscle tissue uses energy, so a reduction in metabolically active tissue can reduce resting energy expenditure. But total daily energy expenditure also depends on body size, physical activity, age, diet, adaptive changes in metabolism and other physiological factors.

During weight loss, the body generally requires fewer calories because there is less tissue to maintain and because energy expenditure can adapt. Therefore, a person may find that the calorie intake that previously maintained a heavier body weight now maintains a lighter body weight.

This is one reason weight maintenance can become difficult after substantial weight loss. It is not necessary to assume that the medication has permanently damaged the metabolism.

A better way to describe the issue: Rapid or substantial weight loss can reduce lean tissue and energy expenditure. Preserving muscle and maintaining physical activity can help protect physical function and improve the quality of weight loss, but weight regulation is controlled by many biological systems rather than muscle alone.

Why Does Weight Come Back After Stopping GLP-1 Medication?

Weight regain after discontinuation is one of the strongest findings in the clinical literature on anti-obesity pharmacotherapy.

In the STEP 1 extension, adults who had received semaglutide 2.4 mg for 68 weeks regained an average of 11.6 percentage points of body weight during the following year after treatment stopped. That represented approximately two-thirds of their previous weight loss. Cardiometabolic improvements also moved back toward baseline for many measures. [3]

A similar pattern was observed in the SURMOUNT-4 randomized withdrawal trial of tirzepatide. Participants who discontinued tirzepatide and switched to placebo regained substantial weight, while those who continued treatment maintained and extended their weight reduction. [4]

These findings support an important concept: obesity is treated as a chronic, relapsing disease in many clinical frameworks. A medication that works while it is being taken does not necessarily create a permanent biological reset once it is discontinued.

The World Health Organization's 2025 guideline therefore describes GLP-1 therapies as an option for long-term obesity treatment in adults, alongside healthy diet, regular physical activity and professional support. The recommendation is conditional because important questions remain around long-term effectiveness and safety, maintenance and discontinuation, costs and health-system capacity. [5]

Protein and Muscle Preservation During GLP-1 Treatment

Reduced appetite is one of the reasons these medications work. It is also one reason some patients may unintentionally eat too little protein or too few total nutrients.

Current expert recommendations therefore emphasize adequate protein intake, dietary quality and resistance exercise during incretin-based treatment.

A 2025 global working-group review recommended protein intake above 1.2 g/kg/day for many adults using GLP-1 therapies, together with protein distribution across meals and structured resistance training. This is a practical consensus target rather than a universal prescription: protein requirements vary according to age, body size, kidney function, activity level, total energy intake and other clinical factors. [6]

For people with kidney disease or other conditions affecting protein needs, an individualized plan is particularly important.

What a muscle-supportive diet looks like

Instead of focusing exclusively on calories, consider the overall nutritional quality of the food being eaten during weight loss.

Meals can emphasize protein-rich foods such as fish, eggs, poultry, dairy or fortified alternatives, tofu and other soy foods, legumes where tolerated, and lean meats. A variety of fruits, vegetables, whole grains and other minimally processed foods can provide fiber, micronutrients and other components of a balanced diet.

Because GLP-1 therapies may cause nausea, early satiety, reflux, constipation or other gastrointestinal symptoms, eating enough may become difficult. Smaller meals, slower eating and individualized symptom management can be more practical than trying to force large meals.

Do not turn a protein target into a rigid rule. People with kidney disease, significant gastrointestinal problems, frailty, eating disorders, or other medical conditions may require a different approach. Protein goals should be individualized by a qualified healthcare professional when medical issues are present.

Resistance Training Is Central to Muscle Preservation

Resistance exercise gives the body a reason to retain and rebuild muscle during a calorie deficit.

This can include weight machines, free weights, resistance bands or appropriately challenging body-weight exercises. The exact program should be adapted to age, fitness, injury history and medical status.

The 2026 meta-analysis found the most favorable lean-mass proportion when resistance training was incorporated into the weight-loss strategy. Other expert reviews similarly recommend progressive resistance exercise, adequate protein and monitoring of body composition and physical performance during incretin-based treatment. [1] [7]

Muscle preservation is not only about appearance

Maintaining muscle supports strength, mobility, balance and the ability to perform everyday tasks.

For older adults, frail individuals and people beginning treatment with already-low muscle mass, the functional implications may be more important than a change in a DXA number alone.

That is why a modern GLP-1 weight-management plan should ask two separate questions:

1. How much weight did I lose?
2. What happened to my strength, physical function and body composition while I lost it?

How to Monitor Muscle During GLP-1 Weight Loss

Body weight alone is a poor way to judge the quality of weight loss.

Measure	Why it matters	Practical use
Body weight	Shows the direction and magnitude of weight change.	Track trends rather than individual day-to-day readings.
Waist circumference	Provides information about central adiposity.	Useful alongside weight and other metabolic measurements.
Strength	Provides functional information about muscle performance.	Track selected exercises or clinician-appropriate strength tests.
Physical function	Reflects the real-world effect of weight loss.	Observe walking, stairs, balance and daily activities.
Body composition	Separates fat and lean compartments better than body weight alone.	DXA or another validated method may be appropriate in selected patients.
Protein and food intake	Low intake can increase nutritional risk during appetite suppression.	Review dietary adequacy, especially when appetite is very low.

Consumer bioelectrical-impedance devices can be useful for tracking trends, but their estimates can vary with hydration, meals and other factors. They should not be treated as equivalent to research-grade DXA or clinical assessment.

What the 2026 Poison-Center Data Really Show

The Mercola article [12] highlighted an important 2026 pharmacovigilance study of GLP-1 receptor agonist exposures reported to U.S. poison centers.

Researchers analyzed 10,033 reported exposures in the National Poison Data System from 2012 through 2023. There were 3,113 exposures before July 2021 and 6,920 afterward. Semaglutide represented 64.2% of the post-approval reports. Most cases involved unintentional therapeutic errors, and gastrointestinal symptoms were common. The proportion of cases managed in or referred to a healthcare facility rose from 23.0% to 33.5%. [8]

These numbers deserve attention, but they need to be interpreted correctly.

Poison-center reports are not the same thing as the incidence of adverse effects among all people taking GLP-1 medications. The study is descriptive pharmacovigilance research. Reporting volume can be influenced by the size of the exposed population, public awareness, clinical practice and reporting behavior. The investigators explicitly noted that the data cannot establish causality. [8]

The most useful lesson is therefore not that “GLP-1 drugs are dangerous,” but that correct prescribing, dose escalation, patient education and medication-use instructions matter as these therapies become more widely used.

What About the Gut Microbiome and Natural GLP-1?

GLP-1 is a naturally occurring hormone produced by specialized enteroendocrine cells in the intestine. Food intake, nutrients, gut signaling and microbial metabolites can influence gastrointestinal hormone secretion.

Short-chain fatty acids such as butyrate are an active area of research because microbial fermentation of dietary fiber can influence host metabolism and gut signaling. However, this research does not justify the claim that a particular dietary protocol can reliably “restore your own GLP-1” and reproduce the clinical effects of pharmacological GLP-1 receptor agonism.

That distinction is important for health communication. A healthy diet rich in minimally processed foods and appropriate fiber can support overall cardiometabolic health, but it should not be presented as a proven replacement for medically indicated anti-obesity treatment.

Likewise, claims that universally eliminating seed oils, restricting linoleic acid to a specific gram target, or consuming a fixed amount of carbohydrate will restore GLP-1 physiology are not supported by the clinical evidence required to make such recommendations universal.

Evidence principle: Mechanistic findings about the microbiome are valuable for research, but mechanistic plausibility is not the same as proof that a dietary intervention produces clinically meaningful weight loss or reproduces the effects of a prescription incretin medication.

A Practical GLP-1 Muscle-Preservation Framework

For someone using or considering an incretin-based medication, the evidence supports a whole-system approach rather than treating the injection as the entire intervention.

1. Establish the reason for treatment

Obesity pharmacotherapy should be based on medical need, health risks, treatment goals and patient preferences. Current guidelines describe obesity treatment as a comprehensive process rather than a medication-only intervention. [9]

2. Protect protein intake

Reduced appetite can make it harder to consume enough protein. A clinician or registered dietitian can help establish an individualized target, with many recent consensus recommendations using more than 1.2 g/kg/day as a practical starting point for many adults. [6]

3. Perform progressive resistance exercise

Resistance training should be treated as a core component of muscle preservation rather than a secondary option. The program can be adapted for beginners, older adults and people with limitations.

4. Avoid unnecessarily aggressive weight loss

Rapid, substantial weight loss can increase the nutritional and functional challenge of maintaining lean tissue. The appropriate rate of weight loss depends on the individual and the treatment plan.

5. Manage gastrointestinal symptoms early

Nausea, vomiting, diarrhea, constipation and early satiety can interfere with hydration, food intake and protein intake. Persistent or severe symptoms warrant medical assessment rather than simply trying to “push through.”

6. Monitor strength and function

A declining number on the scale is not automatically a declining health outcome. Track strength, mobility and daily performance alongside body weight and waist circumference.

7. Plan for long-term maintenance

Do not assume that stopping a medication will automatically preserve the weight loss achieved during treatment. Clinical trials demonstrate substantial weight regain after withdrawal of semaglutide and tirzepatide in many participants. [3] [4]

A maintenance plan should therefore be discussed before treatment starts, including what happens if the medication becomes unavailable, poorly tolerated, unaffordable or medically inappropriate.

Are GLP-1 Medications Still Beneficial?

The muscle question should not obscure the evidence that incretin-based therapies can provide substantial benefits for appropriately selected patients.

In the SELECT cardiovascular-outcomes trial, semaglutide 2.4 mg reduced major adverse cardiovascular events in adults with overweight or obesity, established cardiovascular disease and no diabetes compared with placebo. [10]

WHO and other clinical guidelines therefore recognize GLP-1-based pharmacotherapy as one component of comprehensive obesity treatment rather than dismissing it because lean mass can decline during weight loss. [5] [9]

The balanced conclusion: The fact that lean mass can decline during GLP-1-associated weight loss is clinically relevant. It is not, by itself, evidence that the medication produces more harmful weight loss than lifestyle intervention, nor is it evidence that all patients experience clinically important muscle dysfunction. The goal should be fat loss with preservation of muscle, strength, nutrition and physical function.

What About Newer Obesity Drugs?

The obesity-drug field is continuing to evolve rapidly. Semaglutide remains a major GLP-1-based therapy, while tirzepatide combines GLP-1 and GIP receptor activity. Newer multi-receptor candidates are also being studied.

As of September 2026, retatrutide remains an investigational triple agonist rather than an FDA-approved obesity medication. Its development illustrates why future weight-loss research is increasingly asking not only how much weight can be lost, but also what happens to lean mass, physical function and long-term maintenance. [11]

Regulatory status can change, and drug approvals differ by country. Always verify the current indication with the relevant national regulator and prescribing information.

2026 Evidence Snapshot

Question	Current evidence
Do GLP-1/incretin therapies reduce lean mass?	Yes. Measurable lean-mass reductions occur during substantial weight loss.
Does that mean they uniquely destroy skeletal muscle?	No. Current evidence shows a substantial lean-mass component, but similar proportional lean-mass loss can occur with lifestyle weight loss.
Can resistance training help?	Yes. The 2026 meta-analysis found the most favorable lean-mass proportion with lifestyle intervention plus resistance training.
Is adequate protein important?	Yes. Recent expert consensus supports adequate protein intake during incretin-based therapy.
Does weight commonly return after discontinuation?	Yes. Withdrawal studies of semaglutide and tirzepatide show substantial regain in many participants.
Does weight regain prove permanent metabolic damage?	No. Regain is consistent with obesity's chronic biology and with withdrawal of an effective treatment.
Do poison-center reports prove GLP-1 medications are unsafe?	No. They document reported exposures and outcomes but cannot establish population-level adverse-event incidence or causality.

Frequently Asked Questions

Do GLP-1 medications cause muscle loss?

They can be associated with reductions in lean mass during substantial weight loss. However, current evidence does not show that GLP-1 therapies uniquely or inevitably destroy skeletal muscle. A substantial lean-mass component is also seen during non-drug weight loss. [1]

How much muscle do people lose on semaglutide?

There is no single percentage that applies to every person. Body-composition results vary according to the study, duration of treatment, amount of total weight lost, measurement method and population. Importantly, “lean mass” should not automatically be interpreted as pure skeletal muscle.

How much lean mass is lost with tirzepatide?

In a DXA substudy of SURMOUNT-1, tirzepatide was associated with a 10.9% reduction in lean mass by week 72, while approximately 25% of total weight lost was lean mass and 75% fat mass. [2]

Can protein prevent muscle loss on GLP-1 drugs?

Adequate protein supports muscle maintenance, but no dietary intervention can guarantee that all lean mass will be preserved during substantial weight loss. Protein should be combined with resistance training and adequate overall nutrition.

Does resistance training help preserve muscle on GLP-1 medication?

Current evidence and expert consensus support resistance training as an important strategy for preserving lean mass and physical function during weight loss. [1] [7]

Will I regain weight if I stop semaglutide?

Weight regain is common after treatment withdrawal. In the STEP 1 extension, participants regained about two-thirds of their prior weight loss during the year after semaglutide was discontinued. Individual outcomes vary. [3]

Does tirzepatide also cause weight regain after stopping?

Yes. In SURMOUNT-4, participants who switched from tirzepatide to placebo regained substantial amounts of weight, whereas those who continued treatment maintained and increased their weight reduction. [4]

Are GLP-1 drugs unhealthy because they cause muscle loss?

That conclusion is not supported by the current evidence. These medications can produce clinically meaningful weight loss and other health benefits in appropriate patients. The more evidence-based concern is whether treatment is being accompanied by adequate nutrition, resistance exercise, monitoring and a realistic long-term maintenance strategy.

What is the most important thing to track besides body weight?

Strength and physical function are particularly valuable. Waist circumference, dietary adequacy and, when clinically appropriate, body-composition measurements can provide additional information about the quality of weight loss.

Bottom Line

GLP-1 medications can change body composition, not just body weight. Some of the weight lost can come from lean tissue, and this deserves attention—especially in older adults, people with low baseline muscle mass, and anyone experiencing very rapid or nutritionally compromised weight loss.

But the 2026 evidence does not support the simple claim that GLP-1 medications uniquely “destroy muscle” or permanently “break” metabolism. The best current evidence suggests that lean-mass loss is part of substantial weight reduction across multiple approaches, while resistance training and adequate protein can improve the body-composition profile.

At the same time, withdrawal studies make another point clear: long-term weight management matters. Semaglutide and tirzepatide can produce major weight loss, but stopping treatment often leads to substantial regain. That is better understood as part of the chronic biology of obesity than as proof of medication-induced metabolic damage.

The most useful goal is therefore not simply to become lighter.

The goal is to reduce excess fat while preserving muscle, strength, nutritional status, physical function and long-term health.

Related OneDayMD resource:
Explore the GLP-1 Muscle Loss: Protein, Resistance Training & Body Composition Guide for a deeper practical discussion of muscle preservation during incretin-based weight loss.

References and Primary Sources

1. Lean Mass Changes With Incretin Therapy Versus Lifestyle Intervention: A Systematic Review and Meta-Analysis of Randomised Controlled Trials. Diabetes, Obesity and Metabolism, 2026. PMID: 41877354. PubMed
2. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. Diabetes, Obesity and Metabolism, 2025. PMID: 39996356. DOI: 10.1111/dom.16275. PubMed
3. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, Obesity and Metabolism, 2022. PMID: 35441470. DOI: 10.1111/dom.14725. PubMed
4. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA, 2024. PMID: 38078870. DOI: 10.1001/jama.2023.24945. PubMed
5. WHO issues global guideline on the use of GLP-1 medicines in treating obesity. World Health Organization, December 1, 2025. WHO
6. Optimizing GLP-1 therapies for obesity and diabetes management. 2025 global working-group review and consensus recommendations. PMID: 41322078. PubMed
7. Muscle health in the modern era of incretin-based therapies. European Journal of Clinical Investigation, 2025. PMID: 41328795. PubMed
8. National Poison Center Trends in GLP-1 Receptor Agonist Exposures Following FDA Approval for Weight Loss. Journal of Medical Toxicology, 2026;22:275-285. PMID: 41634285. DOI: 10.1007/s13181-026-01121-z. PubMed
9. Pharmacotherapy for obesity management in adults: 2025 clinical practice guideline update. CMAJ, 2025. PMID: 40789597. DOI: 10.1503/cmaj.250502. PubMed
10. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine, 2023. PMID: 37952131. DOI: 10.1056/NEJMoa2307563. PubMed
11. Retatrutide: current development and regulatory status. Eli Lilly, accessed September 2026. Lilly
12. Mercola.com, “Not All Weight Reduction on GLP-1 Meds Is Healthy, Cardiologist Warns,” September 22, 2026. This page is an independent evidence review and does not reproduce the source article. View the original article.

Medical disclaimer: This article is for educational and informational purposes only. It is not medical advice, diagnosis or treatment. GLP-1 receptor agonists and related medicines are prescription therapies with contraindications, warnings, drug interactions and potential adverse effects. Treatment decisions should be made with a qualified healthcare professional who knows the patient's medical history. Drug indications and regulatory status can vary by country and may change over time.